|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
ARCA Biopharma, Inc. |
|---|---|
| Information provided by: | ARCA Biopharma, Inc. |
| ClinicalTrials.gov Identifier: | NCT00073515 |
Purpose
This trial is for patients with a central venous catheter (a vascular access device) that is not functioning properly (unable to withdraw blood). The trial compares a new blood clot dissolving agent (alfimeprase) against the currently used treatment.
| Condition | Intervention | Phase |
|---|---|---|
|
Catheters, Indwelling |
Drug: Alfimeprase |
Phase II |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double-Blind, Active Control, Single Group Assignment, Safety/Efficacy Study |
| Official Title: | A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Alfimeprase for Restoring Function in Occluded Central Venous Catheters |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Subjects must:
Contacts and Locations
More Information
| Study ID Numbers: | HA003, NuCath-1 |
| Study First Received: | November 21, 2003 |
| Last Updated: | February 16, 2007 |
| ClinicalTrials.gov Identifier: | NCT00073515 History of Changes |
| Health Authority: | United States: Food and Drug Administration |
|
central venous access device thrombosis central venous catheter thrombolysis fibrinolysis |
|
Thrombosis |